Latest Capital Raises News

Atomo Diagnostics has closed a modest Share Purchase Plan, raising $44,500 and issuing free attaching options, while reserving a substantial shortfall for future placement.

Gratifii Limited has secured $10 million in new capital to acquire Simplicity Loyalty and invest strategically in Marketplacer, aiming to broaden its loyalty and rewards platform across Australia and New Zealand.

Australian Dairy Nutritionals has closed the gap on its recent Entitlement Offer by placing 25 million shortfall shares, raising an additional $0.7 million and bringing total proceeds to $1.2 million.

Chariot Resources has broadened its Nigerian lithium acquisition by adding a key small-scale mining licence and converting three leases to mining leases, extending the acquisition timeline and increasing regulatory costs.

Classic Minerals has restated its 80% beneficial interest in the Forrestania Gold Project, emphasizing that recent acquisitions by Forrestania Resources do not affect its rights, which remain protected amid ongoing Supreme Court litigation.

Viridis Mining has delivered strong infill drilling results at its Colossus Rare Earth Project, boosting resource confidence and underpinning an imminent resource and reserve upgrade ahead of a Final Investment Decision in Q3 2026.

Vicinity Centres has secured Eastern Creek Quarter, a hybrid retail hub in Western Sydney, for $400 million, boosting its metropolitan Sydney presence and outlet network.

Australian Oil Company Limited has completed its first crude oil lifting from the Emu Apple Oil Field, marking a key step in its Surat Basin development with steady production and active exploration underway.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Catalina Resources has secured a significant portfolio of gold and base metal projects in Western Australia's Mid-West and Lake Johnston regions, backed by a $3 million capital raise to accelerate exploration and development.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.